CEFMINOX

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H21N7O7S3
Molecular Weight	519.576
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O

InChI

InChIKey=JSDXOWVAHXDYCU-VXSYNFHWSA-N

InChI=1S/C16H21N7O7S3/c1-22-15(19-20-21-22)33-4-7-3-32-14-16(30-2,13(29)23(14)10(7)12(27)28)18-9(24)6-31-5-8(17)11(25)26/h8,14H,3-6,17H2,1-2H3,(H,18,24)(H,25,26)(H,27,28)/t8-,14-,16+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C16H21N7O7S3
Molecular Weight	519.576
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://cefminox-sodium.blogspot.ru/2012/05/cefminox-sodium-apollo-9191-46-950-950.html
Curator's Comment: Description was created based on several sources, including http://www.toku-e.com/Cefminox-sodium-P646.aspx and http://www.ncbi.nlm.nih.gov/pubmed/9517922

Cefminox is a broad-spectrum, bactericidal cephalosporin antibiotic. It is especially effective against Gram-negative and anaerobic bacteria. It is indicated in treatment of the following infections caused by sensitive bacteria: 1. Respiratory infections: Amygdalitis, circumtonsillar abscess, bronchitis, bronchiolitis, bronchiectasis (in fection), secondary infections of chronic respiratory diseases, pneumonia, and pulmonary suppuration; 2. Infection in urinary system: Nephropyelitis, cystitis; 3. Infections in abdominal cavity: Cholecystitis' angiocholitis'peritonitis; 4. Infections in pelvic cavity: Pelvic peritonitis, adnexitis, intrauterine infection, inflammation in pelvic dead space, and parametritis; 5. Septicaemia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Escherichia coli growth 23 Target ID: Escherichia coli growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/25672407	Inhibitor 8504
Peptidoglycan biosynthesis 20 Target ID: map00550 Sources: http://www.genome.jp/dbget-bin/www_bget?D01909+D07642	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Bronchitis 51 Sources: http://cefminox-sodium.blogspot.ru/2012/05/cefminox-sodium-apollo-9191-46-950-950.html	Curative	Preclinical	Unknown Approved Use Unknown
Pneumonia 91 Sources: http://cefminox-sodium.blogspot.ru/2012/05/cefminox-sodium-apollo-9191-46-950-950.html	Curative	Preclinical	Unknown Approved Use Unknown
Cystitis 27 Sources: http://cefminox-sodium.blogspot.ru/2012/05/cefminox-sodium-apollo-9191-46-950-950.html	Curative	Preclinical	Unknown Approved Use Unknown
Septicaemia 15 Sources: http://cefminox-sodium.blogspot.ru/2012/05/cefminox-sodium-apollo-9191-46-950-950.html	Curative	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
In Vitro Analysis of Activities of 16 Antimicrobial Agents against Gram-Negative Bacteria from Six Teaching Hospitals in China.	2015	25672407
Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.	2014	25068396
Synthesis of cefminox by cell-free extracts of Streptomyces clavuligerus.	2000-01-15	10620685
In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds.	1998-03	9517922
Cefminox: correlation between in-vitro susceptibility and pharmacokinetics and serum bactericidal activity in healthy volunteers.	1994-01	8157579

Patents

Sample Use Guides

In Vivo Use Guide

Administration only for intravenous injection or intervenous drop injection. For intravenous injection: Cefminox sodium 1g (valence) can be dissolved in 200ml water for injection, and 5~10% glucose or 0.9% sodium chloride injection. For intervenous drop injection: Cefminox sodium 1g (valence) can be dissolved in 100~500ml 5~10% glucose or 0.9% sodium chloride injection. A drop innjection for 1~2 hours. Recommended dose for adults: 1g (valence) to be administrated twice a day; Adjusted according to the age and symptoms; In septicaemia, and refractory or severe infections, a total daily dosage of 6g (valence) is divided into 3~4 administrations. Recommended dose for children: 20mg (valence)/kg (body weight) to be administrated 3~ 4 times a day.

Route of Administration: Intravenous

In Vitro Use Guide

The MIC50 and MIC90 of cefminox against E. coli were 1.0 mg/L and 4.0 mg/L, respectively.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:41:04 GMT 2025` Edited by `admin` on `Wed Apr 02 07:41:04 GMT 2025`
Record UNII	PW08Y13465
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CEFMINOX

Official Name

English

CEFMINOX [MI]

Preferred Name

English

cefminox [INN]

Common Name

English

Cefminox [WHO-DD]

Common Name

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((((2S)-2-AMINO-2-CARBOXYETHYL)THIO)ACETYL)AMINO)-7-METHOXY-3-(((1-METHYL-1H-TETRAZOL-5-YL)THIO)METHYL)-8-OXO-, (6R,7S)-

Systematic Name

English

(6R,7S)-7-(2-(((S)-2-AMINO-2-CARBOXYETHYL)THIO)ACETAMIDO)-7-METHOXY-3-(((1-METHYL-1H-TETRAZOL-5-YL)THIO)METHYL)-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID

Systematic Name

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-((((2-AMINO-2-CARBOXYETHYL)THIO)ACETYL)AMINO)-7-METHOXY-3-(((1-METHYL-1H-TETRAZOL-5-YL)THIO)METHYL)-8-OXO-, (6R-(6.ALPHA.,7.ALPHA.,7(S*)))-

Systematic Name

English

MT-141 FREE ACID

Code

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-((2-(((2S)-2-AMINO-2-CARBOXYETHYL)THIO)ACETYL)AMINO)-7-METHOXY-3-(((1-METHYL-1H-TETRAZOL-5-YL)THIO)METHYL)-8-OXO-, (6R,7S)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C357